TMCnet News
Genetic Technologies Announces Appointment of Swisstec as Non-Exclusive Asian DistributorMELBOURNE, Australia, July 30, 2018 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG) (Nasdaq:GENE) (“Company”, “GTG”), a diversified molecular diagnostics company embracing blockchain technologies across genomic testing platforms, is pleased to announce that it has entered into a non-exclusive distribution agreement with Swisstec Health Analytics Ltd. (“Swisstec”). This agreement grants Swisstec the right to explore opportunities to deliver GTG’s genetic screening tests to hospital networks in Asia. As a provider of radiology solutions, Swisstec has established relationships with hospitals and healthcare organisations in the region and can assist GTG in the development of distribution channels for a suite of genetic screening tests. The Agreement is supplemental to the Heads of Agreement between the parties announced to the market on 19 June 2018 and represents a significant step in GTG’s plans to enter new markets and expand global adoption of its predictive risk assessment tests. Dr Paul Kasian, Genetic Technologies’ Chairman commented: “This agreement expands on our collaboration with Swisstec and gives us the means to investigate ways we can improve patient outcomes through genetic screening for disease in Asia.” FOR FURTHER INFORMATION PLEASE CONTACT Dr Paul Kasian Jason Wong (USA) About Genetic Technologies Limited Genetic Technologies is developing a pipeline of risk assessment products including a novel colorectal cancer (CRC) test. For more information, please visit www.gtgcorporate.com About Swisstec Health Analytics Ltd Safe Harbor Statement Any statements in this press release that relate to the Company's expectations are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act. The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees. Since this information may involve risks and uncertainties and are subject to change at any time, the Company's actual results may differ materially from expected results. Additional risks associated with Genetic Technologies' business can be found in its periodic filings with the SEC.
|